IDEXX Laboratories Announces a New Fructosamine Test to Help Veterinarians Better Manage Diabetic Patients (Canada) [Trade]
The new fructosamine slide for the Catalyst Dx Chemistry Analyzer provides rapid and accurate fructosamine levels to aid in the management and diagnosis of diabetic dogs and cats
WESTBROOK, Maine, November 05, 2013—IDEXX Laboratories announces the addition of fructosamine testing to its unparalleled test menu for the Catalyst Dx Chemistry Analyzer. With a single fructosamine slide, veterinarians can get an average of blood glucose levels for the previous 2–3 weeks using just one blood sample with results available during the client visit. When run in support of glucose curves, fructosamine testing with the Catalyst Dx analyzer provides a more complete view of patient health, facilitating diabetes management for patients, clients and staff.
“Many veterinarians over the years have asked IDEXX to develop an accurate and affordable point- of-care fructosamine test,” said Tina Hunt, Director, IDEXX VetLab Chemistry. “We’re now pleased to fulfill this request with the new fructosamine slide for the Catalyst Dx Chemistry Analyzer, which provides accurate results in less than 9 minutes. When assessed with blood glucose levels, the veterinarian is now able to modify insulin therapy, educate clients and address any questions or concerns, all within the appointment time frame.”
Managing diabetes in cats and dogs is a stressful, labour-intensive and lifelong process for pets and pet owners. For cats, accurately measuring blood glucose is especially difficult, as the natural feline response to stress can cause blood glucose levels to spike. Fructosamine levels are not sensitive to stress and excitement and can offer a more reliable assessment of underlying glucose levels in those patients. Additionally, by assessing an average of the blood glucose levels over the previous 2–3 weeks, fructosamine testing provides a more robust picture of glucose regulation and is recommended by the American Animal Hospital Association, in addition to blood glucose curves, to monitor the diabetic dog and cat.1
“A diabetes diagnosis presents a range of challenges for pets, clients and practitioners,” said J. Catharine Scott-Moncrieff, VetMB, MS, MA, DACVIM, DECVIM, Purdue University College of Veterinary Medicine. “Therapy and monitoring can be very complex and difficult for everyone involved, which often has a negative effect on compliance. Point-of-care fructosamine testing with the Catalyst Dx analyzer allows for real-time concurrent interpretation of the blood glucose curve and fructosamine, while at the same time reducing stress and frustration for the owner and veterinarian.”
The fructosamine slide was developed through collaboration with some of the world’s leading endocrinologists for advanced accuracy and excellent correlation to a reference laboratory environment with virtually no effect from hemolytic samples.
Fructosamine is the latest addition to the expanding test menu available exclusively on the Catalyst Dx analyzer. Prior to fructosamine, the most recent addition was phenobarbital.
The fructosamine slide will be available to ship in early January 2014. To order, call your authorized distributor representative. To learn more about the Catalyst Dx Chemistry Analyzer and its unparalleled menu of exclusive tests, call 1-800-355-2896 or go to idexx.ca/catalyst.
About IDEXX In-house Analyzers
IDEXX analyzers help veterinarians provide Real-Time Care: timely answers that allow face-to-face conversations with clients, increasing their understanding and improving treatment plan compliance. The IDEXX analyzers’ in-house diagnostic capabilities include clinical chemistry; electrolytes; hematology with an advanced five-part differential and reticulocyte count, band neutrophil and nucleated red blood cell parameters and body fluid analysis; endocrinology; blood gas; coagulation; urinalysis; and infectious diseases. The IDEXX VetLab Station, an in-house laboratory information management system, integrates results from all the analyzers and SNAP point-of-care tests into a single comprehensive and easy-to-use patient report that facilitates client communication. VetConnect PLUS brings all IDEXX diagnostic results together—in-house, reference laboratory or both—for faster, more confident diagnoses. In addition, IDEXX in-house instruments are supported by IDEXX SmartService Solutions, which delivers proactive service over the Internet.
About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. IDEXX is also a worldwide leader in providing livestock and poultry diagnostic tests and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 5,500 people and offers products to customers in more than 175 countries.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” and similar words and expressions. These statements are based on management's current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. Factors that could cause or contribute to such differences include the following: the Company’s ability to develop, manufacture, introduce and market new products and enhancements to existing products; disruptions, shortages or pricing changes that affect the Company’s purchases of products and materials from third parties, including from sole source suppliers; the Company’s ability to manufacture complex biologic products; the effect of government regulation on the Company’s business, including government decisions about whether and when to approve the Company’s products and decisions regarding labeling, manufacturing and marketing products; the Company’s ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; the impact of distributor purchasing decisions on sales of the Company’s products that are sold through distribution; the effects of operations outside the U.S., including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the effects of interruptions to the Company’s operations due to natural disasters or system failures. The reports filed by the Company pursuant to United States securities laws contain discussions of these risks and uncertainties. The Company assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review the Company's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at www.sec.gov, at various SEC reference facilities in the United States and via the Company's website at www.idexx.com).
Director, IDEXX VetLab Chemistry